Search

Displaying results 581 - 590 of 10000 in total
  1. Drug

    Volrubigene ralaparvovec

    go.drugbank.com/drugs/DB16785
    Investigational

    Volrubigene ralaparvovec is under investigation in clinical trial NCT03223194 (Gene Transfer Clinical Study in Crigler-najjar Syndrome).

    Synonyms: Non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene
  2. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.

  3. Drug

    Pemetrexed

    go.drugbank.com/drugs/DB00642
    ApprovedInvestigational

    Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907] … Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta.

  4. Drug

    Methionine

    go.drugbank.com/drugs/DB00134
    ApprovedInvestigationalNutraceutical

    A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.

    Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, Vamin N
  5. Drug

    Ketotifen

    go.drugbank.com/drugs/DB00920
    ApprovedInvestigational

    [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis. … [A231204] In the US, it is now used in an over-the-counter ophthalmic formulation for the treatment of itchy eyes associated with allergies,[L32278] and in Canada a prescription-only oral formulation is

    Products: Nu-ketotifen Syrup - 1mg/5ml
  6. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It is approved for use in Canada and other countries around the world, but not in the US. … [L31808] It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs of anxiety.

  7. Drug

    Tobramycin

    go.drugbank.com/drugs/DB00684
    ApprovedInvestigational

    [L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics … [A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to

  8. Drug

    Amikacin

    go.drugbank.com/drugs/DB00479
    ApprovedInvestigationalVet approved

    of patients with the disease who do not respond to traditional treatment. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population

    Synonyms: 1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin A, -D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-
  9. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]

  10. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. … The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease